(R)-ND-336 NEW
| Price | $2140 | $2785 | $3520 |
| Package | 25mg | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: (R)-ND-336 | CAS No.: 2252493-33-5 |
| Supply Ability: 10g | Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | (R)-ND-336 |
| Description | (R)-ND-336 is a highly potent and selective MMP-9 inhibitor with a K_i value of 19 nM and also exhibits inhibitory activity against MMP-2 (K_i = 127 nM) and MMP-14 (K_i = 119 nM). With significant potential, (R)-ND-336 is being investigated in diabetic foot ulcers (DFUs) research [1]. |
| In vitro | (R)-ND-336 exhibits minimal inhibition of other MMPs, with an inhibition constant (K i ) greater than 100 μM. It possesses a prolonged residence time of 300 minutes, indicative of the duration it remains bound to MMP-9. Moreover, (R)-ND-336 demonstrates a promising IC50 value of 143 μM, resulting in a therapeutic index ratio of 7530. This highlights its significant selectivity for MMP-9 over other MMPs without being cytotoxic [1]. |
| In vivo | (R)-ND-336, applied topically at 50 μg per wound daily over a 14-day period, significantly enhances wound healing, as evidenced by accelerated healing rates. Pharmacokinetic measurements reveal that (R)-ND-336 achieves an area under the curve (AUC) of 1.3 μM·min following topical administration and 35 μM·min after intravenous administration, with a resultant AUC ratio (topical to intravenous) of 3.7%. This indicates that topical application results in minimal systemic absorption in the db/db mouse model. Specifically, the study utilized female db/db mice, aged 8 weeks and weighing approximately 40g, to assess the compound's efficacy. The findings demonstrate not only accelerated wound healing but also the complete inhibition of MMP-9 enzyme activity, thus proving (R)-ND-336's potential therapeutic benefits. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Inhibitors Related | Rhamnose monohydrate | Doxycycline (hyclate) | Chondroitin sulfate | Astragaloside IV | Doxycycline | Edaravone | Glucosamine | Anethole | Meloxicam | Chloramphenicol | Propoxur | Methylchloroisothiazolinone/Methylisothiazolinone Mixture |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2170.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-04-20 | |
| $59.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
|
VIP5Y
|
XINXIANG RUNYU MATERIAL CO., LTD.
|
2026-04-29 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY